Mga Batayang Estadistika
| LEI | 549300BE5DY1HW7IHA64 |
| CIK | 1061983 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cytokinetics, Incorporated
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1. |
|
| September 3, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 2, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 2, 2025 |
CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM MAPLE-HCM PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Aggregate Maximum Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0. |
|
| August 7, 2025 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation Exhibit 3.6 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOKINETICS, INCORPORATED CYTOKINETICS, INCORPORATED, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: FIRST: The name of the corporation is CYTOKINETICS, INCORPORATED. SECOND: The date on which the Ce |
|
| August 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 7, 2025 |
CYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U. |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 S-8 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2025 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation EX-4.7 Exhibit 4.7 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOKINETICS, INCORPORATED CYTOKINETICS, INCORPORATED, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: FIRST: The name of the corporation is CYTOKINETICS, INCORPORATED. SECOND: The date on which |
|
| May 16, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 6, 2025 |
CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1. |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 10, 2025 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| March 31, 2025 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 27, 2025 |
Exhibit 10.22 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (this “Agreement”) is entered into as of November 18, 202 |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 27, 2025 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.9 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exi |
|
| February 27, 2025 |
Exhibit 4.7 CYTOKINETICS, INCORPORATED AND , AS TRUSTEE FORM OF INDENTURE DATED AS OF Debt Securities CYTOKINETICS, INCORPORATED FORM OF INDENTURE THIS INDENTURE, dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and deliver |
|
| February 27, 2025 |
EXHIBIT 10.21 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment to License and Collaboration Agreement This AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), dated as of December 17, 2024, is entered |
|
| February 27, 2025 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM February 27, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cytokinetics, Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s co |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4) Amount of Registration Fee(4) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| February 27, 2025 |
Incentive Compensation Recoupment Policy EXHIBIT 97.1 Cytokinetics, Incorporated Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Cytokinetics, Incorporated, a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment o |
|
| February 27, 2025 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.10 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organiz |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-5 |
|
| February 27, 2025 |
Insider Trading Policies and Procedures EXHIBIT 19.1 CYTOKINETICS, INCORPORATED STOCK TRADING POLICY Effective as of January 2, 2025 1. PURPOSE In an effort to comply with federal and state securities laws governing (a) trading in Cytokinetics, Incorporated (the “Company”) securities while in the possession of “material nonpublic information” concerning the Company, and (b) tipping or disclosing material nonpublic information to outside |
|
| February 27, 2025 |
Description of Director Compensation Exhibit 10.33 DESCRIPTION OF DIRECTOR COMPENSATION Our non-employee director compensation program consists of both a cash component and an equity component. Non-employee directors are also able to elect to receive their annual base retainers in equity, as further described below. We do not compensate members of the Board of Directors or committees on a per-meeting basis. Annual Retainers Our non-e |
|
| February 27, 2025 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.11 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi |
|
| February 27, 2025 |
Exhibit 99.1 CYTOKINETICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China Topline Results from MAPLE-HCM Expected in Q2 2025 Company Provides 2025 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31 |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 S-3ASR 1 d778918ds3asr.htm S-3ASR As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 94-3291317 (State or other jurisdictio |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2024 |
Exhibit 10.2 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE ("Sixth Amendment") is made and entered into as of July 30, 2024 (the "Effective Date"), by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated July 24, 2019 ( |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 7, 2024 |
Employment Offer Letter between Cytokinetics, Incorporated and Brett Pletcher Exhibit 10.1 August 13, 2024 Brett Pletcher 442 Serenity Point Drive Henderson, NV 89012 Dear Brett, I am pleased to offer you a position with Cytokinetics, Inc. (the "Company"), as EVP, Chief Legal Officer, in the Legal Department. In this role, you will be a remote employee performing services at your usual residence at Henderson, Nevada and report directly to Robert Blum, Chief Executive Office |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 9, 2024 |
Employment Offer Letter between Cytokinetics, Incorporated and Sung H. Lee Exhibit 10.1 March 28, 2024 Sung H. Lee 2121 Webster St. #509 San Francisco, CA 94115 Dear Sung, I am pleased to offer you a position with Cytokinetics, Inc. (the "Company"), as EVP, Chief Financial Officer, in the Accounting & Finance Department. In this role, you will report directly to Robert Blum, Chief Executive Officer. This offer is contingent, however, on the items listed on the second pag |
|
| August 9, 2024 |
Exhibit 10.3 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THIRD AMENDMENT AND CONSENT This THIRD AMENDMENT AND CONSENT (this “Third Amendment”), effective as of May 22, 2024 (the “Third Amendment Effective Date”), |
|
| August 9, 2024 |
Exhibit 10.4 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AMENDMENT NO. 1 TO REVENUE PARTICIPATION RIGHT PURCHASE AGREEMENT This Amendment No. 1 To Revenue Participation Right Purchase Agreement, dated as of May 22 |
|
| August 9, 2024 |
Exhibit 10.7 CYTOKINETICS, INCORPORATED COMMON STOCK OPTION PURCHASE AGREEMENT THIS COMMON STOCK OPTION AND PURCHASE AGREEMENT (the “Agreement”) is made as of May 22, 2024 (the “Execution Date”) by and between Cytokinetics, Incorporated, a Delaware corporation (the “Company”), and Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Investor”). Capitalized terms |
|
| August 9, 2024 |
Exhibit 10.6 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. CK-586 Revenue Participation Right Purchase Agreement By and Between Cytokinetics, Incorporated and Royalty Pharma Investments 2019 ICAV Dated as of May 22, |
|
| August 9, 2024 |
Exhibit 10.5 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 2024 DEVELOPMENT FUNDING LOAN AGREEMENT THIS 2024 DEVELOPMENT FUNDING LOAN AGREEMENT (as the same may from time to time be amended, modified, supplemented o |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETI |
|
| August 8, 2024 |
CYTOKINETICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten; Company Has Initiated Rolling NDA Submission FDA Cleared Protocol Amendment for FOREST-HCM Reducing Frequency of Echocardiographic Monitoring Required During Maintenance Treatment ~$1. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 7, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 5, 2024 |
Exhibit 99.1 As we had previously stated, throughout 2023, Cytokinetics engaged in Business Development discussions with potential strategic partners with respect to aficamten. Leading up to and after our late December 2023 disclosure of top-line results from SEQUOIA-HCM, the Phase 3 clinical trial of aficamten, Cytokinetics was approached by one of the third parties with whom we had previously en |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 3, 2024 |
As filed with the Securities and Exchange Commission on June 3, 2024 As filed with the Securities and Exchange Commission on June 3, 2024 Registration No. |
|
| June 3, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0. |
|
| May 28, 2024 |
Exhibit 1.1 Cytokinetics, Incorporated 9,803,922 Shares of Common Stock Underwriting Agreement May 22, 2024 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10017 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Cytokinetics, Incorporated, a Delaware corporation (the “Company”), pr |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 28, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 24, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268483 PROSPECTUS SUPPLEMENT (To prospectus dated November 18, 2022) 9,803,922 shares Common stock We are offering 9,803,922 shares of our common stock at a price per share of $51.00 pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Select Market under the t |
|
| May 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| May 22, 2024 |
Exhibit 99.1 EMPOWERING muscle EMPOWERING lives Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor |
|
| May 22, 2024 |
SUBJECT TO COMPLETION, DATED MAY 22, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268483 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying pros |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 22, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 22, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 17, 2024 |
Cytokinetics, Incorporated Amended and Restated 2015 Employee Stock Purchase Plan CYTOKINETICS, INCORPORATED 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY THE STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED AND APPROVED BY THE STOCKHOLDERS: May 13, 2020 AMENDED AND RESTATED AND APPROVED BY THE STOCKHOLDERS: May 15, 2024 1. |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2024 |
CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM SEQUOIA-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2024 CONGRESS AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment Interruptions Due to Low LVEF Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif. |
|
| May 13, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2024 |
CYTOKINETICS ANNOUNCES ADDITIONAL RESULTS FROM SEQUOIA-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2024 CONGRESS Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif. |
|
| May 10, 2024 |
Description of Director Compensation Exhibit 10.1 DESCRIPTION OF DIRECTOR COMPENSATION Our non-employee director compensation program consists of both a cash component and an equity component. Non-employee directors are also able to elect to receive their annual base retainers in equity, as further described below. We do not compensate members of the Board of Directors or committees on a per-meeting basis. Annual Retainers Our non-em |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINET |
|
| May 10, 2024 |
Form of Performance Stock Unit Award Agreement Exhibit 10.2 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 FIRSTNAME-MIDDLENAME-LASTNAME ADDRESSLINE1 ADDRESSLINE2 CITY, STATE-COUNTRY-ZIPCODE Award Number: Plan: ID: OPTIONNUMBER EQUITYPLAN EMPLOYEEIDENTIFIER Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorpora |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2024 |
CYTOKINETICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Initiated Enrollment in CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population with Obstructive HCM Announced Topline Data from the Phase 1 Study of CK-586; Phase 2 Clinical Trial to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 8, 2024 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 05, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 28, 2024 |
Incentive Compensation Recoupment Policy EXHIBIT 97.1 Cytokinetics, Incorporated Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Cytokinetics, Incorporated, a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment o |
|
| February 28, 2024 |
EXHIBIT 10.6 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE ("Fifth Amendment") is made and entered into as of November 27, 2023 (the "Effective Date"), by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated July 24, 20 |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS, |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 27, 2024 |
CYTOKINETICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit New Drug Application for Aficamten to FDA in Q3 2024 and Marketing Authorization Application to EMA in Q4 2024 Primary Results from SEQUOIA-HCM Are Expected to be Presented at an Upcoming Medical Conference in Q2 2024 Company Provides 2024 Financial Guidance; Approximately 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif. |
|
| February 13, 2024 |
CYTK / Cytokinetics, Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0726-cytokineticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Cytokinetics Inc Title of Class of Securities: Common Stock CUSIP Number: 23282W605 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate th |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Cytokinetics, Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 23282W605 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 17, 2023 |
AMENDED AND RESTATED BYLAWS OF CYTOKINETICS, INCORPORATED (as amended and restated on November 16, 2023) Table of Contents Page Article I CORPORATE OFFICES 1 1. |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 2, 2023 |
CYTOKINETICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS On Track for Topline Results from SEQUOIA-HCM a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Initiated Enrollment in ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif. |
|
| October 19, 2023 |
©2023 CYTOKINETICS, All Rights Reserved. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looki |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 06, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Cytokinetics, Incorporated (Exact name of Registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or other jurisdiction of incorporation or org |
|
| October 3, 2023 |
Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description Exhibit 10.1 CYTOKINETICS, INCORPORATED EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (Adopted by the Compensation and Talent Committee on September 26, 2023) 1. Introduction. The purpose of this Cytokinetics, Incorporated Executive Severance Plan (the “Plan”) is to provide assurances of specified severance benefits to eligible employees of the Company whose employment is involuntarily ter |
|
| August 3, 2023 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation EXHIBIT 3.5 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOKINETICS, INCORPORATED CYTOKINETICS, INCORPORATED, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: FIRST: The name of the corporation is CYTOKINETICS, INCORPORATED. SECOND: The date on which the Ce |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 3, 2023 |
CYTOKINETICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Clinical Trial Comparing Aficamten and Metoprolol in Obstructive HCM ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM, Expected to Start in September 2023 Company Reduces Projected Spending by Approximately 15% and Revises 2023 Financial Spending Guidance SOUTH SAN FRANCISCO, Calif. |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 23, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 23, 2023 |
CYTOKINETICS PRESENTS NEW DATA IN PATIENTS WITH NON-OBSTRUCTIVE HCM FROM COHORT 4 OF REDWOOD-HCM IN LATE-BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2023 CONGRESS Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023 SOUTH SAN FRANCISCO, Calif. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 4, 2023 |
CYTOKINETICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European Society of Cardiology Heart Failure 2023 Congress Company to Reduce Spending by More Than 10% in 2023 to Maintain Over 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 7, 2023 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 27, 2023 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 04, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2023 |
Exhibit 10.23 SECOND AMENDMENT This SECOND AMENDMENT (this “Amendment”), effective as of December 8, 2022, is executed by and between ROYALTY PHARMA DEVELOPMENT FUNDING, LLC, a Delaware limited liability company (“RP” and the “Lender” and together with RP’s affiliates, successors and/or assignees that become Lenders hereunder, collectively but not jointly, the “Lenders”) and CYTOKINETICS, INCORPOR |
|
| March 1, 2023 |
Exhibit 10.22 CONSENT AND AMENDMENT This CONSENT AND AMENDMENT (this “Amendment”), effective as of June 30, 2022, is executed by and between ROYALTY PHARMA DEVELOPMENT FUNDING, LLC, a Delaware limited liability company (“RP” and the “Lender” and together with RP’s affiliates, successors and/or assignees that become Lenders hereunder, collectively but not jointly, the “Lenders”) and CYTOKINETICS, I |
|
| March 1, 2023 |
Form of Option Agreement (Director Annual Grant) Exhibit 10.13 Notice of Grant of Stock Options and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have the |
|
| March 1, 2023 |
Form of Option Agreement (Employee Annual Grant) Exhibit 10.11 Notice of Grant of Stock Options and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have the |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS, |
|
| March 1, 2023 |
Form of Option Agreement (New Hire Inducement) Exhibit 10.12 Notice of Grant of Stock Options and Option Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have th |
|
| March 1, 2023 |
Form of Option Agreement (Director Onboarding) Exhibit 10.14 Notice of Grant of Stock Options and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State, Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have the sa |
|
| March 1, 2023 |
CYTOKINETICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company Provides 2023 Financial Guidance; More than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif. |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
Certificate of Change of Registered Agent Exhibit 4.9 STATE OF DELAWARE CERTIFICATE OF CHANGE OF REGISTERED AGENT AND/OR REGISTERED OFFICE The corporation organized and existing under the General Corporation Law of the State of Delaware hereby certifies as follows: 1. The name of the corporation is CYTOKINETICS, INCORPORATED 2. The Registered Office of the corporation in the State of Delaware is changed to 251 Little Falls Drive (street), |
|
| March 1, 2023 |
Form of Restricted Stock Unit Award Agreement (Employee Annual Grant) Exhibit 10.15 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 First and Last Name Address line 1 Address line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have |
|
| March 1, 2023 |
Exhibit 10.28 Cytokinetics, Incorporated Shares of Common Stock (par value $0.001 per share) Amended and Restated Controlled Equity OfferingSM Sales Agreement March 1, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cytokinetics, Incorporated, a Delaware corporation (the “Company”), confirms its amended and restated agreement (this “Agreement”) with Cantor Fit |
|
| March 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common stock, par value $0. |
|
| March 1, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268483 PROSPECTUS SUPPLEMENT (To Prospectus dated November 18, 2022) $300,000,000 Common Stock We have entered into an amended and restated Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co., dated March 1, 2023. In accordance with the terms of the Amended and Restated Controlled Equity OfferingSM |
|
| March 1, 2023 |
Exhibit 10.5 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE ("Fourth Amendment") is made and entered into as of October 12, 2022, by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated July 24, 2019 (the "Original Lea |
|
| March 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2023 |
Amended and Restated 2004 Equity Incentive Plan Exhibit 10.9 CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 10 |
|
| March 1, 2023 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Cytokinetics, Incorporated (“we,” “our,” or “us,”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per share (the “Common Stock”). The following summary set |
|
| March 1, 2023 |
Form of Restricted Stock Unit Award Agreement (Employee Key Performer) Exhibit 10.16 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have |
|
| March 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0. |
|
| March 1, 2023 |
Form of Restricted Stock Unit Award Agreement (Director Annual Grant) Exhibit 10.17 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have |
|
| February 24, 2023 |
Compensation Information for the Company’s Named Executive Officers Compensation Information for the Company’s Named Executive Officers Robert I. Blum, President & Chief Executive Officer: · 2023 base salary $790,000; · 2022 bonus award $395,705; and · 2023 target bonus is 75% of base salary. Ching W. Jaw, Senior Vice President, Finance and Chief Financial Officer: · 2023 base salary $525,971; · 2022 bonus award $193,145; and · 2023 target bonus is 45% of base sal |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 17, 2023 |
AMENDED AND RESTATED BYLAWS OF CYTOKINETICS, INCORPORATED (as amended and restated on February 14, 2023) 280969645 v2 Table of Contents Page Article I CORPORATE OFFICES 1 1. |
|
| February 9, 2023 |
CYTK / Cytokinetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Cytokinetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23282W605 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R |
|
| February 6, 2023 |
CYTK / Cytokinetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cytokinetics, Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 23282W605 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 9, 2023 |
EX-99.1 2 cytk-ex991.htm EX-99.1 Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements in |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 8, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 18, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4) Amount of Registration Fee(4) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| November 18, 2022 |
EX-4.8 Exhibit 4.8 CYTOKINETICS, INCORPORATED AND , AS TRUSTEE FORM OF INDENTURE DATED AS OF Debt Securities CYTOKINETICS, INCORPORATED FORM OF INDENTURE THIS INDENTURE, dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and |
|
| November 18, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.12 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organi |
|
| November 18, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.10 Exhibit 4.10 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organiz |
|
| November 18, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.11 Exhibit 4.11 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association |
|
| November 18, 2022 |
As filed with the Securities and Exchange Commission on November 18, 2022 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 18, 2022 Registration No. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 4, 2022 |
Description of Director Compensation Exhibit 10.1 DESCRIPTION OF DIRECTOR COMPENSATION Our non-employee director compensation program consists of both a cash component and an equity component. Non-employee directors are also able to elect to receive their annual base retainers in equity, as further described below. We do not compensate members of the Board of Directors or committees on a per-meeting basis. Annual Retainers Our non-em |
|
| November 3, 2022 |
CYTOKINETICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 SEQUOIA-HCM Continuing with Results Expected in 2H 2023; Patient Screening for Cohort 4 of REDWOOD-HCM Closed with Data Expected in 1H 2023 COURAGE-ALS Continuing Following First Interim Analysis, Enrollment Expected to Complete in 1H 2023 SOUTH SAN FRANCISCO, Calif. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 02, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 4, 2022 |
CYTOKINETICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif. |
|
| July 6, 2022 |
Exhibit 4.1 EXECUTION VERSION CYTOKINETICS, INCORPORATED and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of July 6, 2022 3.50% Convertible Senior Notes due 2027 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 15 Section 2. |
|
| July 6, 2022 |
CYTOKINETICS ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING Exhibit 99.1 CYTOKINETICS ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) ? Cytokinetics, Incorporated (?Cytokinetics?) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027 (the ?notes?) in a private offering to qu |
|
| July 6, 2022 |
CYTOKINETICS ANNOUNCES PRICING OF $450 MILLION CONVERTIBLE SENIOR NOTES OFFERING Exhibit 99.2 CYTOKINETICS ANNOUNCES PRICING OF $450 MILLION CONVERTIBLE SENIOR NOTES OFFERING SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) ? Cytokinetics, Incorporated (?Cytokinetics?) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 (the ?notes?) in a private offering to qualified inst |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 30, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 24, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 15, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 16, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 13, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 31, 2022 |
As filed with the Securities and Exchange Commission on May 31, 2022 As filed with the Securities and Exchange Commission on May 31, 2022 Registration No. |
|
| May 31, 2022 |
Amended and Restated 2004 Equity Incentive Plan. Exhibit 99.1 CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 10 |
|
| May 31, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $ 0. |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 23, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 18, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 17, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 10, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 4, 2022 |
EXHIBIT 99.1 Cytokinetics Reports First Quarter 2022 Financial Results Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch Readiness Activities and Buildout of Commercial Infrastructure in Advance of PDUFA Date of November 30, 2022 for Omecamtiv Mecarbil SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLO |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 12, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 CYTOKINETICS, INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 8, 2022 |
CYTK / Cytokinetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Cytokinetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23282W605 Date of Event Which Requires Filing of this Statement: March 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| April 8, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 2, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 3, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 1, 2022 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EXHIBIT 99.1 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2022 it granted stock options to purchase an aggregate of 165,600 shares of common stock to eighteen new employees, whose employment commenced in March 2022, as a materia |
|
| April 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 2, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 CYTOKINETICS, INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 1, 2022 |
Compensation Information for the Company’s Named Executive Officers Exhibit 99.1 Compensation Information for the Company?s Named Executive Officers Robert I. Blum, President & Chief Executive Officer: ? 2022 base salary $742,410; ? 2021 bonus award $428,314; and ? 2022 target bonus is 65% of base salary. David W. Cragg, Chief Human Resources and Administration Officer: ? 2022 base salary $431,502; ? 2021 bonus award $161,813; and ? 2022 target bonus is 45% of bas |
|
| March 1, 2022 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) EXHIBIT 99.1 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2022 it granted stock options to purchase an aggregate of 86,850 shares of common stock to eight new employees, whose employment commenced in February 2022, as a mater |
|
| March 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 28, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 25, 2022 |
Exhibit 10.15 [ * ] ? CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (the ?Agreement?) is made as of December 20, 2021 (the ?Clo |
|
| February 25, 2022 |
Exhibit 10.14 [ * ] ? CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. LICENSE AND COLLABORATION AGREEMENT This License and Collaboration Agreement (this ?Agreement?) is made as of December 20, 2021 (the ?Effective Date?), by |
|
| February 25, 2022 |
Exhibit 10.21 [ * ] ? CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Revenue Participation Right Purchase Agreement By and Between Cytokinetics, Incorporated and Royalty Pharma Investments 2019 ICAV Dated as of January 7, 20 |
|
| February 25, 2022 |
Exhibit 10.18 [ * ] ? CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. DEVELOPMENT FUNDING LOAN AGREEMENT THIS DEVELOPMENT FUNDING LOAN AGREEMENT (as the same may from time to time be amended, modified, supplemented or restate |
|
| February 25, 2022 |
Exhibit 10.17 [ * ] ? CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (the ?Agreement?) is made as of December 20, 2021 (the ?Clo |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS, |
|
| February 25, 2022 |
Exhibit 10.16 [ * ] ? CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (the ?Agreement?) is made as of December 20, 2021 (the ?Clo |
|
| February 25, 2022 |
Exhibit 10.4 THIRD AMENDMENT TO OFFICE LEASE This THIRD AMENDMENT TO OFFICE LEASE ("Third Amendment") is made and entered into as of the 12th day of November, 2021, by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant"). r e c i t a l s : A.Landlord and Tenant entered into that certain Office Lease |
|
| February 25, 2022 |
Exhibit 10.20 [ * ] ? CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AMENDMENT NO. 1 TO ROYALTY PURCHASE AGREEMENT This Amendment No. 1 To Royalty Purchase Agreement, dated as of January 7, 2022, (this ?Amendment?), is made |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 24, 2022 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Cytokinetics Reports Fourth Quarter 2021 Financial Results Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil in Advance of PDUFA Date of November 30, 2022 SEQUOIA-HCM Open to Enrollment; Development Program for Aficamten Expanding in 2022 Company Provides 2022 Financial Guidance; More Than 2 Years of Cash Runway SOUTH SAN FRANCIS |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 23, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 16, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 16, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 15, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2022 |
CYTK / Cytokinetics, Inc. / DRIEHAUS CAPITAL MANAGEMENT LLC - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cytokinetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23282W605 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 9, 2022 |
CYTK / Cytokinetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0703-cytokineticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Cytokinetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23282W605 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate t |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 4, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 1, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 1, 2022 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EXHIBIT 99.1 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2022 it granted stock options to purchase an aggregate of 200,700 shares of common stock to 15 new employees, whose employment commenced in January 2022, as a material i |
|
| January 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 24, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 7, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 20, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 20, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 10, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 9, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 1, 2021 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EXHIBIT 99.1 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2021 it granted stock options to purchase an aggregate of 143,500 shares of common stock to 9 new employees, whose employment commenced in November 2021, as a material |
|
| December 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 15, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOK |
|
| November 5, 2021 |
Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of June 30, 2021, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?), the Len |
|
| November 5, 2021 |
Amended and Restated 2004 Equity Incentive Plan Exhibit 10.2 CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 10 |
|
| November 5, 2021 |
As filed with the Securities and Exchange Commission on November 5, 2021 As filed with the Securities and Exchange Commission on November 5, 2021 Registration No. |
|
| November 3, 2021 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Cytokinetics Reports Third Quarter 2021 Financial Results Submission of NDA for Omecamtiv Mecarbil on Track to Occur in Q4 2021 Start-Up Activities Underway for SEQUOIA-HCM Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2022 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 1, 2021 |
Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) EXHIBIT 99.1 Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 29, 2021 it granted stock options to purchase an aggregate of 68,550 shares of common stock to 8 new employees, whose employment commenced in October 2021, as a material ind |
|
| November 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 29, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 13, 2021 |
CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION FILED VIA EDGAR. |
|
| October 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 7, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 7, 2021 |
Exhibit 99.1 Program to begin at 8:30 AM ET N o t F o r P r o m ot io n a l U s e , F o r I n v e s t o r s O n ly Forward - Looking Statements Charting the Commercial Course : Analyst & Investor Day 2021 N o t fo r P r o m ot i o n a l U s e , F o r I n v e s t o r s O n l y 2 This Presentation contains forward - looking statements for purposes of the Private Securities Litigation Reform Act of 1 |
|
| October 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 1, 2021 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EXHIBIT 99.1 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2021 it granted stock options to purchase an aggregate of 206,300 shares of common stock to 14 new employees, whose employment commenced in September 2021, as a materi |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 12, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 1, 2021 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EXHIBIT 99.1 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2021 it granted stock options to purchase an aggregate of 113,600 shares of common stock to 10 new employees, whose employment commenced in August 2021, as a material in |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 19, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 13, 2021 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETI |
|
| August 6, 2021 |
Exhibit 10.1 EIGHTH AMENDMENT TO LEASE This EIGHTH AMENDMENT TO LEASE (this ?Eighth Amendment?) is made and entered into as of May 18, 2021, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (?Landlord?), and CYTOKINETICS, INC., a Delaware corporation (?Tenant?). r e c i t a l s : A.Landlord and Tenant (as successor in interest to MetaXen, LLC and Exelixis, |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 5, 2021 |
EXHIBIT 99.1 Cytokinetics Reports Second Quarter 2021 Financial Results Submission of NDA for Omecamtiv Mecarbil on Track to Occur in 2H 2021 Positive Results from REDWOOD-HCM Support Progression of Aficamten (CK-274) to Pivotal Phase 3 Trial in Patients with Obstructive Hypertrophic Cardiomyopathy Expected to Start in Q4 Pivotal Phase 3 Trial of Reldesemtiv in Patients with ALS Now Enrolling More |
